Hims & Hers Health

Regulatory Headwinds And Rising Costs Will Hinder Digital Health Scalability

AnalystLowTarget

Not Invested

Consensus Narrative from 11 Analysts

Published

04 May 25

Updated

23 Jul 25

AnalystLowTarget's Fair Value

US$28.00

82.3% overvalued

23 Jul

US$51.05

222.1%

-22.9%

Author's Valuation

US$28.0

82.3% overvalued

AnalystLowTarget Fair Value

Narrative

Updates1

Shared on08 May 25
Fair value Increased 12%

AnalystLowTarget Fair Value

US$28.0

82.3% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

15.92%

Healthcare Services revenue growth rate

0.30%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$268.94m

Earnings '28

30.73x

PE Ratio '28

US$8.26b

Market Cap '28

US$8.26b

Market Cap '28

245.37m

No. shares '28

US$33.68

Share Price '28

US$33.68 Share Price '28

Discounted to 2025 @ 6.40% p.a.

US$27.96

Fair Value '25

Regulatory Headwinds And Rising Costs Will Hinder Digital Health Scalability

Shared on08 May 25Fair value Increased 12%

Shared on08 May 25
Fair value Increased 12%